AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 18(6), 1969, pp. 924-929
Copyright © 1969 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katz, N.
Right arrow Articles by Oliveira, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katz, N.
Right arrow Articles by Oliveira, C. A.

Further Clinical Trials with Hycanthone, a New Antischistosomal Agent*

Naftale Katz, J. Pellegrino AND Celso A. Oliveira
Instituto Nacional de Endemias Rurais, Caixa Postal 1743, Hospital da Policia Militar, and Department de Clínica Médica, Faculdade de Medicina, Belo Horizonte, Brazil

Clinical trials with hycanthone, an active metabolite of lucanthone, were performed in 203 patients with active schistosomiasis mansoni. The drug was administered in the form of enterocoated tablets and by intramuscular injection (sulfamate and methanesulfonate salts). Anorexia, nausea, vomiting, abdominal pain, headache, muscle pain, and loss of body weight were the commonest side-effects. In all but six patients, treatment with enterocoated tablets could be completed. With the parenteral formulations no interruption of treatment was necessary. Alterations of plasma-level transminases and of electro-cardiographic tracings were observed in a few patients. The most promising schedule of treatment seems to be a single intramuscular dose of the methanesulfonate salt of hycanthone (2 to 3 mg per kg) since the cure rate was higher than 90% without appreciable side-effects. Further clinical trials and pilot projects for mass treatment should be encouraged.


* This study was supported, in part, by research grants from the World Health Organization, Geneva, Switzerland, and by the U. S. Public Health Service (AI-05917-06 TMP), National Institutes of Health, Bethesda, Maryland.




This article has been cited by other articles:


Home page
 ScienceHome page
S. H. Rogers and E. Bueding
Hycanthone Resistance: Development in Schistosoma mansoni
Science, June 4, 1971; 172(3987): 1057 - 1058.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1969 by the American Society of Tropical Medicine and Hygiene.